Anavex Life Sciences enters $150M at-the-market equity facility with TD Securities

ANAVEX LIFE SCIENCES CORP.

Sales agreement with TD Securities (USA) LLC for ATM offering of up to $150M in common stock.
Shares sold under shelf registration statement filed July 14, 2025, effective July 23, 2025.
Sales agent commission up to 3.0% of gross proceeds; company not obligated to sell any shares.
Sales may be conducted on Nasdaq or in negotiated transactions; offering can be suspended by either party.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.